As chief medical officer of Trek Therapeutics, Robert Hindes, MD, helps guide a unique for-profit company that follows the principles of a public benefit corporation. Working to address viral conditions such as hepatitis C (HCV), Robert Hindes, MD, and his team are focused on developing effective, affordable drugs that can be distributed worldwide.
Members of the Trek Therapeutics team have written and made presentations on the serious issue of HVC drugs and affordability. This issue persists at a time when cure rate gaps among HIV-co-infected and African American patient populations have finally narrowed and nearly anyone is considered a “treatment candidate.”
However, price transparency does not exist in the market, and the media focuses on the high per-pill costs associated HCV treatment. The sensationalization surrounding the cost of HCV drugs hinders the efforts of treatment advocacy groups to get more patients diagnosed and treated. This has also led to a hesitancy in the medical community to implement general HCV screening programs intended to reduce the reservoir of infected individuals by identifying and treating the large number of undiagnosed HCV infected individuals.
Members of the Trek Therapeutics team have written and made presentations on the serious issue of HVC drugs and affordability. This issue persists at a time when cure rate gaps among HIV-co-infected and African American patient populations have finally narrowed and nearly anyone is considered a “treatment candidate.”
However, price transparency does not exist in the market, and the media focuses on the high per-pill costs associated HCV treatment. The sensationalization surrounding the cost of HCV drugs hinders the efforts of treatment advocacy groups to get more patients diagnosed and treated. This has also led to a hesitancy in the medical community to implement general HCV screening programs intended to reduce the reservoir of infected individuals by identifying and treating the large number of undiagnosed HCV infected individuals.